Brokers Set Expectations for Assembly Biosciences, Inc.'s FY2028 Earnings (NASDAQ:ASMB)

Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 earnings estimates for shares of Assembly Biosciences in a research report issued on Monday, April 1st. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will post earnings of ($15.59) per share for the year. HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($14.77) per share.

Separately, StockNews.com cut shares of Assembly Biosciences from a "hold" rating to a "sell" rating in a report on Thursday, March 28th.

Assembly Biosciences Stock Up 4.7 %

Shares of Assembly Biosciences stock traded up $0.60 on Tuesday, hitting $13.50. 37,039 shares of the company traded hands, compared to its average volume of 29,639. The company has a 50-day moving average price of $12.27 and a 200 day moving average price of $10.62. Assembly Biosciences has a 12-month low of $7.69 and a 12-month high of $20.04. The company has a market cap of $73.98 million, a PE ratio of -0.79 and a beta of 0.57.

Institutional Investors Weigh In On Assembly Biosciences

Large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in Assembly Biosciences during the 1st quarter worth $27,000. JPMorgan Chase & Co. lifted its position in Assembly Biosciences by 15,633.0% during the 1st quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 14,695 shares during the last quarter. Prudential Financial Inc. acquired a new position in Assembly Biosciences during the 2nd quarter worth $36,000. Tower Research Capital LLC TRC lifted its position in Assembly Biosciences by 110.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 8,992 shares during the last quarter. Finally, UBS Group AG lifted its position in Assembly Biosciences by 110.0% during the 4th quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 12,576 shares during the last quarter. 19.92% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Assembly Biosciences news, major shareholder Alexander Schornstein acquired 24,999 shares of the firm's stock in a transaction that occurred on Wednesday, January 17th. The stock was purchased at an average cost of $9.36 per share, for a total transaction of $233,990.64. Following the completion of the acquisition, the insider now owns 655,357 shares of the company's stock, valued at approximately $6,134,141.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders sold 2,066 shares of company stock worth $26,924. Corporate insiders own 4.10% of the company's stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.